TORONTO, Oct. 4, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS"
or the "Company") (TSX: HLS), a pharmaceutical company focused on
central nervous system and cardiovascular markets, announces that
it will be participating in two upcoming live Virtual Non-Deal
Roadshows hosted by Renmark Financial Communications Inc.
Event details are as follows:
- October 5, 2021, at
4:00 PM EDT (1:00 PM PDT). For this event, Renmark is
focused on attracting participants in the Greater Los Angeles area, though other
interested parties are welcome to attend. REGISTER HERE:
https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-tsx-hls-2021-10-05-130000
- October 7, 2021, at
12:00 PM EDT. For this event,
Renmark is focused on attracting participants in the Greater Atlanta area, though other interested
parties are welcome to attend. REGISTER HERE:
https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-tsx-hls-2021-10-07-120000
The events will feature Gilbert
Godin, Chief Executive Officer, and Tim Hendrickson, Chief Financial Officer. The
Company's presentation will be followed by a live Q&A.
Investors interested in participating in an event will need to
register using one of the links above. Registration for a live
event may be limited, but access to the replay after the event will
be available at the investor section of the Company's website.
To ensure smooth connectivity, please access the links using the
latest version of Google Chrome.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a
pharmaceutical company focused on the acquisition and
commercialization of late-stage development, commercial stage
promoted and established branded pharmaceutical products in the
North American markets. HLS's focus is on products targeting the
central nervous system and cardiovascular therapeutic areas. HLS's
management team is composed of seasoned pharmaceutical executives
with a strong track record of success in these therapeutic areas
and at managing products in each of these lifecycle stages. For
more information, please visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.